Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9362665 | 0.77 | HRH3 (0.36) | GAAKMT2APTGS2HRH3ALDH1A1 | |
| SCHEMBL10196841 | 0.77 | GAA (0.40) | GAAKMT2APTGS2HRH3ALDH1A1 | |
| SCHEMBL24077344 | 0.76 | ADRA1A (0.37) | ALDH1A1ADORA1KDM4ESMN1; SMN2ADORA2A | |
| SCHEMBL24076322 | 0.76 | MPO (0.40) | KMT2APTGS2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8149332 | 0.75 | MAPT (0.36) | GAAPTGS2HRH3ALDH1A1HTT | |
| SCHEMBL12877231 | 0.75 | TSHR (0.37) | GAAKMT2APTGS2HRH3ALDH1A1 | |
| SCHEMBL17723466 | 0.75 | PTGS2 (0.36) | GAAKMT2APTGS2HRH3ALDH1A1 | |
| SCHEMBL25280792 | 0.75 | MET (0.39) | GAAKMT2APTGS2HRH3ALDH1A1 | |
| SCHEMBL24246974 | 0.73 | HRH3 (0.37) | GAAKMT2APTGS2HRH3ALDH1A1 | |
| SCHEMBL21384024 | 0.72 | MARS1 (0.43) | GAAKMT2AALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| CN-101835755-B | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2013-12-11 | — | — | CN | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| CN-101835755-A | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| EP-0489327-B1 | Chroman derivatives | MERCK PATENT GMBH (DE) | 1998-05-27 | — | — | EP | disclosed |
| US-5238937-A | PYRIDAZINY OR OXODIHYDROPYRIDAZINYL CHROMAN DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 1993-08-24 | — | — | US | disclosed |
| EP-0489327-A1 | Chroman derivatives | MERCK PATENT GmbH (DE) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GAA 481/4885KMT2A 587/4885PTGS2 519/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | GAA 481/4885KMT2A 587/4885PTGS2 519/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | GAA 3384/4885KMT2A 2703/4885PTGS2 2613/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GAA 481/4885KMT2A 587/4885PTGS2 519/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GAA 481/4885KMT2A 587/4885PTGS2 519/4885 |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GAA 481/4885KMT2A 587/4885PTGS2 519/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | GAA 481/4885KMT2A 587/4885PTGS2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.